KRMD Research | Milton Maxwell

KRMD

KORU Medical Systems, Inc.

5.77

-0.04-0.69%

Dec 16, 4:00:00 PM EST

Upcoming Earnings

Report date

-/-

Earnings Call Transcripts

This Quarter (Q4 '25)

No earnings call transcript available yet

Last Quarter (Q3 '25)

No earnings call transcript available

Key Stats

Market Cap

267.28M

P/E (TTM)

Basic EPS (TTM)

-0.08

Dividend Yield

Recent Filings

8-K

11/25/25Nov 25, 2025

10-Q

11/12/25Nov 12, 2025

8-K

11/12/25Nov 12, 2025

8-K

Q2 revenues hit $10.2M record

8/6/25Aug 6, 2025

KORU Medical Systems reported Q2 2025 net revenues of $10.2 million, up 21% year-over-year, marking its first quarter above $10 million and sixth straight period of double-digit growth. Core business revenues rose 19% to $9.3 million, while pharma services surged 42% to $0.9 million, driving gross profit to $6.5 million at 63.5% margin despite tariff charges. The company raised full-year revenue guidance to $39.5-$40.5 million, expecting positive operating cash flow and cash above $8.1 million. Adam Kalbermatten joined as Chief Commercial Officer to bolster drug delivery partnerships.

10-Q

Q2 FY2025 results

8/6/25Aug 6, 2025

KORU Medical Systems posted Q2 revenues of $10.2 million, up 20.9% year-over-year and 10.6% quarter-over-quarter (derived), fueled by 15.3% domestic core growth from new patient starts and 33.9% international core expansion via market share gains and new geographies, while pharma services rose 42.1%. Gross margin dipped to 63.5% from 65.0% y/y, pressured by tariff charges of $0.1 million, yet operating loss narrowed to $0.3 million from $1.2 million, trimming net loss to $0.2 million or $0.00 per diluted share on 46.2 million shares. YTD, revenues climbed 19.3% to $19.8 million with a $1.4 million net loss, versus $2.9 million last year; operating cash flow used $0.7 million, leaving $8.1 million in cash and full availability on a $5 million revolver maturing 2026. No material M&A or impairments noted. Tariffs may erode margins by less than 100 bps annually, but competition in subcutaneous infusion devices poses ongoing risks.

About

KORU Medical Systems, Inc. develops, manufactures, and commercializes subcutaneous infusion solutions primarily for the subcutaneous drug delivery market in the United States and internationally. The company offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD), chronic inflammatory demyelinating polyneuropathy (CIDP), secondary immunodeficiency disorder (SIDD), and paroxysmal nocturnal hemoglobinuria (PNH). Its products include the FREEDOM60 and FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products. The company was formerly known as Repro Med Systems, Inc. and changed its name to KORU Medical Systems, Inc. in March 2022. KORU Medical Systems, Inc. was incorporated in 1980 and is headquartered in Mahwah, New Jersey.

CEO

Ms. Linda M. Tharby

IPO

4/5/1994

Website

https://www.korumedical.com

Employees

Sector

Healthcare

Industry

Medical Instruments & Supplies